Design and Synthesis of trans-N-[4-[2-(6-Cyano-1,2,3,4-tetrahydroisoquinolin-2- yl)ethyl]cyclohexyl]-4-quinolinecarboxamide (SB-277011): A Potent and Selective Dopamine D3 Receptor Antagonist with High Oral Bioavailability and CNS Penetration in the Rat
- 18 April 2000
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 43 (9) , 1878-1885
- https://doi.org/10.1021/jm000090i
Abstract
A selective dopamine D3 receptor antagonist offers the potential for an effective antipsychotic therapy, free of the serious side effects of currently available drugs. Using clearance and brain penetration studies as a screen, a series of 1,2,3,4-tetrahydroisoquinolines, exemplified by 13, was identified with high D3 affinity and selectivity against the D2 receptor. Following examination of molecular models, the flexible butyl linker present in 13 was replaced by a more conformationally constrained cyclohexylethyl linker, leading to compounds with improved oral bioavailability and selectivity over other receptors. Subsequent optimization of this new series to improve the cytochrome P450 inhibitory profile and CNS penetration gave trans-N-[4-[2-(6-cyano-1,2,3,4-tetrahydroisoquinolin-2-yl)ethyl]cyclohexyl]-4-quinolinecarboxamide (24, SB-277011). This compound is a potent and selective dopamine D3 receptor antagonist with high oral bioavailability and brain penetration in the rat and represents an excellent new chemical tool for the investigation of the role of the dopamine D3 receptor in the CNS.Keywords
This publication has 13 references indexed in Scilit:
- Novel benzopyrano[3,4-c]pyrrole derivatives as potent and selective dopamine D3 receptor antagonistsBioorganic & Medicinal Chemistry Letters, 1999
- The Selective 5-HT1BReceptor Inverse Agonist 1‘-Methyl-5-[[2‘-methyl-4‘- (5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]carbonyl]-2,3,6,7-tetrahydro- spiro[furo[2,3-f]indole-3,4‘-piperidine] (SB-224289) Potently Blocks Terminal 5-HT Autoreceptor Function Both in Vitro and in VivoJournal of Medicinal Chemistry, 1998
- Novel cyclohexyl amides as potent and selective D3 dopamine receptor ligandsBioorganic & Medicinal Chemistry Letters, 1997
- Linking the Family of D2 Receptors to Neuronal Circuits in Human Brain: Insights into SchizophreniaNeuropsychopharmacology, 1997
- 2-[(substituted)phenyl]-5-[1-(2-phenylazacycloheptyl)methyl]-1H-pyrroles with high affinity and selectivity for the dopamine D3 receptorBioorganic & Medicinal Chemistry Letters, 1997
- Elucidation of D3 receptor function in vivo: Do D3 receptors mediate inhibition of dopamine neuronal activity?Biochemical Society Transactions, 1996
- Novel 6-substituted 2-aminotetralins with potent and selective affinity for the dopamine D3 receptorBioorganic & Medicinal Chemistry Letters, 1996
- Localization of dopamine D3 receptor mRNA in the rat brain using in situ hybridization histochemistry: comparison with dopamine D2 receptor mRNABrain Research, 1991
- Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylaseNature, 1990
- Synthesis of analogs of N-(2-chloroethyl)-N'-(trans-4-methylcyclohexyl)-N-nitrosourea for evaluation as anticancer agentsJournal of Medicinal Chemistry, 1977